Mesoblast Limited company information, Employees & Contact Information

Cellular Medicine Leader Mesoblast to Present Full Year 2025 Results and Pipeline Updates Stock Titan

Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access The Manila Times

FDA Approves Mesoblast’s Remestemcel-L for Steroid-Refractory GvHD CGTLive®

191% Revenue Surge: Mesoblast's Historic FDA Win with Ryoncil Transforms Cell Therapy Landscape Stock Titan

Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024 GlobeNewswire

Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs The Manila Times

DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology Diagnostic and Interventional Cardiology

Failure to launch commercially-approved mesenchymal stromal cell therapies: what's the path forward? Proceedings of the International Society for Cell & Gene Therapy (ISCT) Annual Meeting Roundtable held in May 2023, Palais des Congrès de Paris, Orga ScienceDirect.com

First FDA-Approved MSC Therapy: Mesoblast CEO Reveals Breakthrough Details at Major Industry Event Stock Titan

Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® The Manila Times

FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD CGTLive®

Mesoblast Financial Results and Corporate Update Webcast GlobeNewswire

Can Mesoblast's $194K Ryoncil Treatment Generate the Blockbuster Revenue Investors Expect? Stock Titan

Mesoblast Financial Results and Corporate Update Webcast The Manila Times

FDA Issues CRL for Mesoblast's Allogeneic Stem Cell Therapy for SR-Graft-Versus-Host-Disease CGTLive®

Can This Billion-Dollar Healthcare Entrepreneur Transform Mesoblast's Commercial Future? Stock Titan

FDA Deems Mesoblast’s Data on Remestemcel-L Cell Therapy Sufficient for BLA Submission in Pediatric SR-aGVHD CGTLive®

Mesoblast Financial Results and Corporate Update Webcast The Manila Times

Former Westpac Bank CEO Joins Mesoblast Board Following Major FDA Approval Success Stock Titan

Mesoblast's Groundbreaking GVHD Drug Ryoncil Hits $13.2M in First Quarter Sales After FDA Approval Stock Titan

Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022 Yahoo Finance

First FDA-Approved MSC Therapy: Mesoblast's Ryoncil Shows Strong Launch in Children's GvHD Treatment Stock Titan

FDA Awards Mesoblast 20+ Years Market Protection for Breakthrough Pediatric Cell Therapy Ryoncil Stock Titan

69% Increase: Mesoblast's Ryoncil Net Sales Reach $19.1M; J‑Code Active October Stock Titan

J3402 J‑Code Active Oct 1, 2025 — Mesoblast's Ryoncil Gains Permanent Billing Pathway to Broaden Access Stock Titan

Remestemcel-L now available to treat steroid-refractory acute graft-versus-host disease Contemporary Pediatrics

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease OncLive

Mesoblast Scores Double FDA Win: Accelerated Heart Failure Drug Review Plus Ryoncil Success Reaches 220M Lives Stock Titan

Mesoblast Gears Up for Third Push for Remestemcel-L's Approval in GvHD CGTLive®

Mesoblast Submits New Information to FDA IND File in GlobeNewswire

Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility GlobeNewswire

Groundbreaking Cell Therapy Ryoncil Launches in US with Major Insurance Coverage Stock Titan

FDA issues complete response letter to remestemcel-L for graft-versus-host disease treatment Contemporary Pediatrics

Operational Highlights and Financial Results for the Period Ended March 31, 2022 Yahoo Finance

Mesoblast Phase 3 Trial Shows That a Single Injection of GlobeNewswire

Mesoblast Limited (NASDAQ:MESO) CEO Silviu Itescu Says Stock Price Blast Off is Imminent The Wall Street Transcript

FDA Issues CRL to BLA Resubmission for Remestemcel-L in Pediatric Steroid-Refractory aGVHD OncLive

Mesoblast Appoints Leading Pharmaceutical Industry Executive as Chief Medical Officer GlobeNewswire

Intramyocardial Cell Therapy Revascor Gets Orphan Drug Designation Medical Professionals Reference

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy Novartis

Top 10 Regenerative Medicine Companies | Innovative and Rapidly Advancing Market.us Media

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch The Manila Times

Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch MarketScreener

Mesoblast Announces Clearance for European Trial of Revascor Cardiac Stem Cell Product Diagnostic and Interventional Cardiology

Phase 2 Trial Results of Mesoblast’s Cell Therapy Show Dose-Related Improvements in Biologic Refractory Rheumatoid Arthritis BioInformant

Mesoblast Presents 24-Month Trial Results for Chronic Low Back Pain Product Candidate MPC-06-ID BioInformant

Mesoblast Limited (ASX:MSB) Sustained Six-Month Improvement In Heart Muscle Function With Revascor, ABN Newswire